AbbVie and JNJ Clash: Which Healthcare Giant Will Dominate in 2026

AbbVie Inc (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are two healthcare giants with distinct business models. AbbVie focuses on immunology, oncology, and aesthetics, relying heavily on three major wholesale distributors for its U.S. sales. In FY 2025, AbbVie's revenue reached nearly $61.2 billion, representing an 8.7% growth over the previous year.

Johnson & Johnson operates a broader business model, with two primary segments: Innovative Medicine and MedTech. Its pharmaceuticals arm has had two FDA approvals this year and has two more approved drug product launches in the E.U. and U.S. The company's recent buy of Atraverse Medical bolsters its MedTech division.

AbbVie is expected to see significant growth in net income, from $4.2 billion to $14.6 billion, with sales projected to reach $67.2 billion. Johnson & Johnson faces substantial competition and patent litigation risks, but its diversified business model provides stability. The company's pharmaceuticals arm has a robust pipeline beyond pending products.

The Motley Fool Stock Advisor analyst team recommends investing in the 10 best stocks for long-term growth, with AbbVie not being one of them. Johnson & Johnson is an overlooked behemoth, with 28 products and platforms generating more than $1 billion in annual revenue.